Oral octreotide ‘feasible’ alternative acromegaly treatment: study
The capsules have been found non-inferior to the standard injectable therapy, researchers say
Patients with acromegaly may do just as well on oral octreotide treatment as injectable somatostatin receptor ligands, a US-led study shows.
Although the oral formulation of the drug is yet to be approved in Australia, the findings suggest it could be a “favourable alternative” treatment for the growth hormone disorder.
In the phase III clinical trial, an international team of researchers compared the safety and efficacy of oral octreotide capsules compared to injectable somatostatin receptor ligands (iSRLs) in 146 middle-aged adults with acromegaly.
Following an initial run-in phase to gauge treatment response, 37 participants were randomly assigned to iSRLs and 55 to oral octreotide (40mg daily, optional titration to 60mg or 80mg).
